BTG shares take a dive

13 April 2012

ALMOST £50m was wiped from the value of BTG as it announced fresh delays to the launch of its flagship product Varisolve, a treatment for varicose veins.

The technology incubator's stock has more than halved in value since last November when the US Food & Drug Administration raised safety fears about Varisolve, an injectable foam.

The shares tumbled 34p, or a quarter, to 98p yesterday.

BTG is submitting new safety data to the American regulator, but not until mid-2005.

Varisolve accounts for a big part of BTG's valuation and was pencilled in to make peak sales of around £600m, so this latest news comes as a huge blow.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in